127 related articles for article (PubMed ID: 23106890)
1. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.
Hu DY; Huang J; Cai NS; Zhu WL; Li YS; Massaad R; Hanson ME; Dickstein K
Chin Med J (Engl); 2012 Nov; 125(21):3868-74. PubMed ID: 23106890
[TBL] [Abstract][Full Text] [Related]
2. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Konstam MA; Neaton JD; Dickstein K; Drexler H; Komajda M; Martinez FA; Riegger GA; Malbecq W; Smith RD; Guptha S; Poole-Wilson PA;
Lancet; 2009 Nov; 374(9704):1840-8. PubMed ID: 19922995
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
6. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
Pitt B; Segal R; Martinez FA; Meurers G; Cowley AJ; Thomas I; Deedwania PC; Ney DE; Snavely DB; Chang PI
Lancet; 1997 Mar; 349(9054):747-52. PubMed ID: 9074572
[TBL] [Abstract][Full Text] [Related]
9. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Konstam MA; Neaton JD; Poole-Wilson PA; Pitt B; Segal R; Sharma D; Dasbach EJ; Carides GW; Dickstein K; Riegger G; Camm AJ; Martinez FA; Bradstreet DC; Ikeda LS; Santoro EP;
Am Heart J; 2005 Jul; 150(1):123-31. PubMed ID: 16084158
[TBL] [Abstract][Full Text] [Related]
10. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
[TBL] [Abstract][Full Text] [Related]
11. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
12. Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community.
Rochon PA; Sykora K; Bronskill SE; Mamdani M; Anderson GM; Gurwitz JH; Gill S; Tu JV; Laupacis A
J Gen Intern Med; 2004 Jun; 19(6):676-83. PubMed ID: 15209607
[TBL] [Abstract][Full Text] [Related]
13. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B; Poole-Wilson PA; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
Lancet; 2000 May; 355(9215):1582-7. PubMed ID: 10821361
[TBL] [Abstract][Full Text] [Related]
14. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
16. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Erhardt LR
Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
